Epithalon — Wolverine Health

How it works

A synthetic tetrapeptide based on epithalamin, a pineal gland extract researched by the St. Petersburg Institute of Bioregulation since the 1980s. The anti-aging angle: it reportedly activates telomerase and extends telomere length in cell culture. Rodent lifespan studies from that same research group show extended mean lifespan. The telomerase story is interesting. It's also mostly from one lab, in animals, using in vitro measures. Human evidence doesn't yet exist in a rigorous form.

FDA status: No FDA approval. Under PCAC July 23–24 2026 review for 503A bulk substance consideration.
WADA status: Permitted in sport
Route: subcutaneous or intramuscular injection; intranasal

Key studies

Epithalone activates telomerase and elongates telomeres — Khavinson et al. (2003)

Epithalon (Ala-Glu-Asp-Gly) activated telomerase in fetal human fibroblasts and somatic cells, with increased telomere elongation observed in treated cell cultures compared with controls.

Wolverine Health is building physician-supervised peptide protocols. Get early access.

Join the waitlist

Research on Epithalon

What RFK Jr.'s February 2026 announcement actually said about peptides

The "announcement" was a Joe Rogan appearance, not a Federal Register notice. The wellness scene heard one thing. The actual signal was narrower, and the rulemaking that turns it into access is still more than a year away.

After the PCAC votes: what FDA reclassification actually looks like in practice

A favourable July PCAC vote is not a prescription you can fill in August. The rulemaking that follows the recommendation is where the access actually changes — and where the legitimate supply chain starts to exist.

The PCAC review is July 23–24, 2026. Here is what that means for peptide access.

Two days at FDA's White Oak campus decide which of seven peptides US compounding pharmacies will be allowed to dispense by prescription. The vote is not an approval, the docket is not all the peptides, and the framing the forums use is mostly wrong.

Telomere biology for non-biologists: what shortening actually means for ageing

WADA

Telomeres are repetitive DNA caps at chromosome ends; they shorten with cell division. Here is what telomerase actually does, what the human data shows, and where epitalon — the peptide attached to this story — sits in the July 2026 FDA review.

MOTs-C vs Epitalon: two longevity peptides, two evidence standards

WADA

MOTs-C and Epitalon both get sold as longevity peptides. They face the FDA's PCAC review on consecutive days in July for completely different indications. Here is what their two very different evidence standards actually look like.

Epitalon and telomere biology: parsing the signal from the noise

WADA

Epitalon is a four-amino-acid peptide studied for telomerase induction in cultured cells and lifespan in mice. The FDA is reviewing it on July 24 for an insomnia indication. Here's what the evidence actually shows.

Epithalon: Telomere, Anti-Aging Research, and the July 2026 PCAC Review

WADA

Science-journalism overview of Epithalon (Epitalon) — the tetrapeptide studied for telomerase activation and anti-aging effects, its preclinical and limited human evidence base, and its position on the PCAC July 2026 docket.